Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 14/20 | 0.62 |
| ▸ | NTRK1 | P04629 | 6/20 | 0.62 |
| ▸ | AURKB | Q96GD4 | 11/20 | 0.57 |
| ▸ | ABL1 | P00519 | 2/20 | 0.54 |
| ▸ | BCR | P11274 | 2/20 | 0.54 |
| ▸ | EGFR | P00533 | 3/20 | 0.54 |
| ▸ | PLK4 | O00444 | 2/20 | 0.54 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.54 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.54 |
| ▸ | STK25 | O00506 | 1/20 | 0.54 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
| ▸ | GAK | O14976 | 1/20 | 0.54 |
| ▸ | MUSK | O15146 | 1/20 | 0.54 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.54 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.54 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.54 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.54 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.54 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2712009 | 0.94 | AURKA (0.59) | AURKANTRK1AURKBABL1BCR | |
| SCHEMBL1532377 | 0.92 | AURKA (0.55) | AURKANTRK1AURKBABL1BCR | |
| SCHEMBL1054549 | 0.92 | AURKA (0.53) | AURKANTRK1AURKBABL1BCR | |
| SCHEMBL4367242 | 0.91 | AURKA (0.55) | AURKANTRK1AURKBABL1BCR | |
| Cyclopropane Carboxylic Acid SCHEMBL2496532 | 0.90 | AURKA (0.60) | AURKANTRK1AURKBABL1BCR | |
| SCHEMBL1954399 | 0.89 | AURKA (0.59) | AURKANTRK1AURKBABL1BCR | |
| SCHEMBL12338758 | 0.87 | AURKA (0.77) | AURKANTRK1AURKBABL1BCR | |
| SCHEMBL2712007 | 0.87 | AURKA (0.59) | AURKANTRK1AURKBABL1BCR | |
| SCHEMBL2713050 | 0.86 | AURKA (0.57) | AURKANTRK1AURKBABL1BCR | |
| SCHEMBL2201772 | 0.85 | AURKA (0.52) | AURKANTRK1AURKBABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662195-B2 | Protein kinase conjugates and inhibitors | CELGENE CAR LLC (BM) | 2020-05-26 | — | — | US | disclosed |
| US-10662195-B2 | Protein kinase conjugates and inhibitors | CELGENE CAR LLC (BM) | 2020-05-26 | — | — | US | disclosed |
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | CELGENE CAR LLC (BM) | 2017-06-22 | — | — | US | disclosed |
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | CELGENE CAR LLC (BM) | 2017-06-22 | — | — | US | disclosed |
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | CELGENE CAR LLC (BM) | 2017-06-22 | — | — | US | disclosed |
| US-9556426-B2 | Protein kinase conjugates and inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556426-B2 | Protein kinase conjugates and inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556426-B2 | Protein kinase conjugates and inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160153052-A1 | MARKER TO PREDICT AND MONITOR RESPONSE TO AURORA KINASE B INHIBITOR THERAPY | ABBVIE INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-8779127-B2 | Processes for preparing substituted pyrimidines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-07-15 | — | — | US | disclosed |
| US-20100185419-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100185419-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| US-20100185419-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010028236-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20090221602-A1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-09-03 | — | — | US | disclosed |
| US-7557106-B2 | Substituted pyrimidines useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-07-07 | — | — | US | disclosed |
| US-20090105270-A1 | Kinase inhibition and anticancer therapy | BUSER-DOEPNER CAROLYN A | 2009-04-23 | — | — | US | disclosed |
| EP-1746093-A1 | Process for preparing substituted pyrimidines | Vertex Pharmaceuticals Incorporated (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20060270660-A1 | inhibitors of FLT-3, Aurora-1, Aurora-2, and Aurora-3 protein kinases; leukemia; N-{4-[4-(5-Methyl-2H-pyrazol-3-ylmethyl)-6-(4-propyl-piperazin-1-yl)-pyrim- idin-2-ylsulfanyl]-phenyl}-propionamide | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-11-30 | — | — | US | disclosed |
| US-20040049032-A1 | Processes for preparing substituted pyrimidines | VERTEX PHARMACEUTICALS INCORPORATED | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105270-A1 | Kinase inhibition and anticancer therapy | MAP3K20, MAP3K10, MAP3K2 | AURKA 168/4885NTRK1 1031/4885AURKB 68/4885 |
| US-20170174691-A1 | Protein Kinase Conjugates and Inhibitors | MAP3K20, ADK, TTK | AURKA 31/4885NTRK1 1586/4885AURKB 43/4885 |
| US-20060270660-A1 | inhibitors of FLT-3, Aurora-1, Aurora-2, and Aurora-3 protein kinases; leukemia; N-{4-[4-(5-Methyl-2H-pyrazol-3-ylmethyl)-6-(4-propyl-piperazin-1-yl)-pyrim- idin-2-ylsulfanyl]-phenyl}-propionamide | FLT3, AURKA, AURKC | AURKA 2/4885NTRK1 873/4885AURKB 12/4885 |
| US-20090221602-A1 | PROCESSES FOR PREPARING SUBSTITUTED PYRIMIDINES | AURKA, AURKC, AURKB | AURKA 1/4885NTRK1 1305/4885AURKB 3/4885 |
| US-20100185419-A1 | ALGORITHM FOR DESIGNING IRREVERSIBLE INHIBITORS | CDKN1A, SERPINB1, SPR | AURKA 47/4885NTRK1 3951/4885AURKB 36/4885 |
| US-20040049032-A1 | Processes for preparing substituted pyrimidines | AURKA, AURKC, AURKB | AURKA 1/4885NTRK1 1305/4885AURKB 3/4885 |
| US-10662195-B2 | Protein kinase conjugates and inhibitors | MAP3K20, ADK, TTK | AURKA 31/4885NTRK1 1586/4885AURKB 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.